omalizumab [Omalizumab]

tematický
112
Termíny

Xolair

 

Xolair

Perzistentní odkaz   https://www.medvik.cz/link/D000069444
Definice

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

DUI
D000069444 MeSH Prohlížeč
CUI
M0387411
CAS
Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer
Historická pozn.
2016 (2001)
Veřejná pozn.
2016; OMALIZUMAB was indexed under ANTIBODIES, ANTI-IDIOTYPIC and ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2001-2011

D Chemikálie a léčiva
D12.776 proteiny 2 581
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 492
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.071 protilátky anti-idiotypické 61
D12.776.124.486.485.114.071.500 omalizumab 112
D12.776.124.486.485.114.224 monoklonální protilátky 4 659
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 854
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 349
D12.776.124.486.485.114.224.060.313 alemtuzumab 125
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 452
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 42
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 186
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 153
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 263
D12.776.124.486.485.114.224.060.813 natalizumab 157
D12.776.124.486.485.114.224.060.829 nivolumab 449
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 58
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 274
D12.776.124.486.485.114.224.060.937 ustekinumab 121
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 492
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.071 protilátky anti-idiotypické 61
D12.776.124.790.651.114.071.500 omalizumab 112
D12.776.124.790.651.114.224 monoklonální protilátky 4 659
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 854
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 349
D12.776.124.790.651.114.224.060.375 alemtuzumab 125
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 452
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 42
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 186
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 153
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 263
D12.776.124.790.651.114.224.060.813 natalizumab 157
D12.776.124.790.651.114.224.060.829 nivolumab 449
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 58
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 274
D12.776.124.790.651.114.224.060.937 ustekinumab 121
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 492
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.071 protilátky anti-idiotypické 61
D12.776.377.715.548.114.071.500 omalizumab 112
D12.776.377.715.548.114.224 monoklonální protilátky 4 659
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 854
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 349
D12.776.377.715.548.114.224.200.375 alemtuzumab 125
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 452
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 42
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 186
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 153
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 263
D12.776.377.715.548.114.224.200.813 natalizumab 157
D12.776.377.715.548.114.224.200.829 nivolumab 449
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 58
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 274
D12.776.377.715.548.114.224.200.937 ustekinumab 121